...
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer.
【24h】

Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer.

机译:非小细胞肺癌恶性胸腔积液细胞和表皮中表皮生长因子受体突变的检测与比较。

获取原文
获取原文并翻译 | 示例
           

摘要

Cells or cell-free fluid of malignant pleural effusion could be important clinical specimen for epidermal growth factor receptor (EGFR) mutation screening in advanced non-small cell lung cancer (NSCLC) patients. However, their usefulness in mutation detection has not been well compared. In this study we recruited 26 East Asian NSCLC patients with malignant pleural effusion, determined the mutation status of EGFR in both cells and matched cell-free fluid with the use of sequencing and mutant-enriched PCR. After comparing the mutation spectrums, we found both the cells and cell-free pleural fluid may be feasible clinical specimen for EGFR mutation detection in unresectable NSCLC given sensitive genotyping assays employed. Direct sequencing could miss a significant portion of mutations in these heterogeneous specimens. More sensitive methods, such as mutant-enriched PCR and gene scan, could provide more reliable mutational information.
机译:恶性胸腔积液的细胞或无细胞液可能是晚期非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)突变筛查的重要临床标本。但是,它们在突变检测中的用途尚未很好地进行比较。在这项研究中,我们招募了26名患有恶性胸腔积液的东亚非小细胞肺癌患者,并通过测序和突变富集PCR确定了两种细胞和无细胞液中EGFR的突变状态。比较突变谱后,我们发现,在采用敏感的基因分型分析的情况下,不可切除的NSCLC中的细胞和无细胞胸膜液均可作为EGFR突变检测的可行临床标本。直接测序可能会错过这些异质标本中很大一部分突变。更敏感的方法,例如富集突变体的PCR和基因扫描,可以提供更可靠的突变信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号